Adellgene® Friedreich’s Ataxia

Kit for the determination of the GAA triplet repeats number of the FXN gene by fluorescent fragment analysis.

Information about the product

Friedreich’s ataxia (FRDA) is the most common hereditary ataxia and it´s an autosomal recessive degenerative disease.

The most common DNA abnormality associated with Friedreich’s ataxia (FRDA) is the expansion of a GAA triplet repeat polymorphism localized in the first intron of the gene encoding frataxin (FXN). Pathogenic GAA expansion alleles are in the size range of 50 to >1300 repeats with three different intervals:

  • healthy (between 5-30 repeats),
  • Mild symptoms (30-49 repeats)
  • Severe symptoms (50-1300 repeats)

Intended Use

Adellgene® Friedreich’s Ataxia is a semi-automated in vitro diagnostic kit designed for use in clinical laboratories which quantitatively determines the number of repetitions of GAA (guanine-adenine-adenine) in the first intron of the gene encoding frataxin (FXN) located in chromosome 9 resulting in Frie­dreich’s ataxia disease. It aims to aid diagnosis associated with clinical findings in Friedreich’s ataxia that span from mild to severe symptoms.

The use of this kit is the determination of healthy alleles who have between 5 to 30 GAA repeats, patients with mild phenotype (30-49 repeats), and severe (50-1300).

The technology is based on the polymerase chain reaction (PCR) of genomic DNA extracted from peripheral blood followed by fluorescence analysis of the size of the PCR fragments obtained by genetic analyser and conversion of that size in the number of GAA repeats.

Patients who can benefit from this determination are those referred by a specialist. The intended user of the kit is technical personnel trained to carry out the protocol and the interpretation of results described in the instructions for use.

Workflow

workflow adellgene

Results

Adellgene Friedreich s Ataxia Reaction 1 healthy allele 15R
Adellgene Friedreich s Ataxia Reaction 2 mutated allele more than 200R
Adellgene Friedreich s Ataxia title
Adellgene® Friedreich’s Ataxia 5

Limitations

  • Mutations (point mutations, insertions, deletions) at amplification primer sites are possible and may result in the lack of allele definition. Other technologies could be necessary to resolve the genotyping.
  • Data and result interpretation should be revised by qualified personnel.

Area:

Molecular Genetics, Neurology, Targeted study of specific pathologies

Technology:

Documents:

Consult our experts

Google reCaptcha: Invalid site key.

Related products

Agilent SureSelect Human All Exon V8.

High-performance exome for the enrichment of human coding regions, with updated coverage of RefSeq, CCDS and GENCODE, including the TERT promoter and difficult-to-capture exons. 3.- Detailed Description Operating principle SureSelect Human All Exon V8 is based on NGS library preparation and capture enrichment of target regions of the human exome. The workflow is compatible with…
Agilent
Next Generation Sequencing (NGS)

Duplicα RealTime ApoE Genotyping Kit

In vitro diagnostic kit based on real-time PCR for the qualitative detection of the ApoE*E2, ApoE*E3 and ApoE*E4 alleles in human genomic DNA. Detailed Description Operating principle The kit is based on the specific amplification of target sequences by Real-Time PCR, using specific fluorescent probes. Allelic discrimination is performed using labelled probes: FAM (6-carboxyfluorescein) to…
Clonit
Real Time PCR (qPCR)

Twist Custom Panels for NGS Applications

Twist custom panels are highly customisable solutions, allowing the exact selection of regions, genes, pathways or variants of interest. They are designed to offer high performance, flexibility and precision in all types of applications and starting samples. Detailed Description Operating principle: In practice, the use of custom panels makes it possible to overcome the limitations…
SOPHIA Genetics
Next Generation Sequencing (NGS)

SOPHiA DDM™ Community Pharmacogenomics Solution

Pharmacogenomics solution for NGS analysis that combines a capture enrichment kit with the analytical capabilities of the SOPHiA DDM™ platform. It is designed to evaluate and report genomic variants associated with pharmacogenomics in an accelerated manner. Detailed description Operating principle The solution integrates a capture enrichment kit with the bioinformatics analysis of the SOPHiA DDM™…
SOPHIA Genetics
Next Generation Sequencing (NGS)